Investment Rating - The investment rating for the company is "Buy" with a maintained rating for the next six months [6][17]. Core Views - The approval of D-Allulose as a food ingredient marks a significant milestone for the company, positioning it as the second enterprise in China to receive approval for enzyme-based production of D-Allulose, enhancing its competitive edge in the functional sweetener market [3][4]. - The company currently has an annual production capacity of 10,000 tons for D-Allulose and is evaluating the potential for further expansion, indicating a strong growth trajectory in the sweetener segment [3][4]. - The financial projections for the company show a recovery in net profit, with expected figures of 1.17 billion, 2.12 billion, and 2.37 billion yuan for 2025, 2026, and 2027 respectively, reflecting a significant growth rate [4][3]. Summary by Sections Company Overview - The company is recognized for its technological leadership in the functional sweetener sector, particularly with the recent approval of its enzyme product for D-Allulose production [3]. Financial Performance - The projected revenue for 2025 is 6.63 billion yuan, with a growth rate of 25.03% compared to the previous year [4]. - The expected EBITDA for 2025 is 1.83 billion yuan, indicating a strong operational performance [4]. - The net profit for 2025 is projected to be 1.17 billion yuan, with a remarkable growth rate of 110.40% [4]. Market Position - The approval of D-Allulose aligns the company with international standards, as it follows similar approvals in the US, Canada, Australia, and New Zealand, suggesting a robust market potential both domestically and internationally [2][3].

报告期内，百龙创园的益生元、膳食纤维两大系列产品分别实现营收3.22亿元、6.24亿元，同比增长 25.43%、40.42%；占总营收比例分别达到了29.14%、56.35%，是业务发展的重点。健康甜味剂业务实 现营收1.56亿元，同比增长13.85%，占营收比例达到14.12%，成为公司业绩增长的"第二曲线"，其他淀 粉糖（醇）产品则是公司产品线以及满足不同客户需求的重要补充。 本报讯 （记者王僖）4月29日晚，山东百龙创园生物科技股份有限公司（以下简称"百龙创园"）披露 2024年年报和2025年一季报。报告显示，公司2024年实现营业总收入11.52亿元，同比增长32.64%；归 属于上市公司股东的净利润2.46亿元，同比增长27.26%。公司确定的2024年分红预案为拟向全体股东每 10股派发现金红利1.4元（含税）并以资本公积转增3股。 作为功能性食品配料领域的龙头，百龙创园主要从事益生元系列产品、膳食纤维系列产品、健康甜味剂 系列产品和其他淀粉糖（醇）产品的研发、生产及销售。 全球化布局下，2024年，百龙创园境外收入达6.98亿元，同比增长58.42%；占主营业务营收的比例达 63.08%，同比 ...